JP2002510643A - 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用 - Google Patents

狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用

Info

Publication number
JP2002510643A
JP2002510643A JP2000542029A JP2000542029A JP2002510643A JP 2002510643 A JP2002510643 A JP 2002510643A JP 2000542029 A JP2000542029 A JP 2000542029A JP 2000542029 A JP2000542029 A JP 2000542029A JP 2002510643 A JP2002510643 A JP 2002510643A
Authority
JP
Japan
Prior art keywords
antibody
cells
cell
lupus
cd40cr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000542029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002510643A5 (OSRAM
Inventor
ランドルフ・ジェイ・ノエル
クリストファー・エム・バーンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of JP2002510643A publication Critical patent/JP2002510643A/ja
Publication of JP2002510643A5 publication Critical patent/JP2002510643A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2000542029A 1998-04-03 1999-04-02 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用 Withdrawn JP2002510643A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
US09/054,488 1998-04-03
PCT/US1999/007321 WO1999051258A1 (en) 1998-04-03 1999-04-02 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
JP2002510643A true JP2002510643A (ja) 2002-04-09
JP2002510643A5 JP2002510643A5 (OSRAM) 2006-05-11

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000542029A Withdrawn JP2002510643A (ja) 1998-04-03 1999-04-02 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用

Country Status (9)

Country Link
EP (1) EP1067954A4 (OSRAM)
JP (1) JP2002510643A (OSRAM)
KR (1) KR20010072564A (OSRAM)
CN (2) CN100352497C (OSRAM)
AU (1) AU743824B2 (OSRAM)
HU (1) HUP0101689A3 (OSRAM)
NO (1) NO20004966L (OSRAM)
TW (1) TWI224969B (OSRAM)
WO (1) WO1999051258A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
NZ337072A (en) * 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
CN1173735C (zh) 2004-11-03
HUP0101689A3 (en) 2004-08-30
NO20004966L (no) 2000-12-04
AU3379699A (en) 1999-10-25
EP1067954A1 (en) 2001-01-17
EP1067954A4 (en) 2004-08-18
CN100352497C (zh) 2007-12-05
TWI224969B (en) 2004-12-11
NO20004966D0 (no) 2000-10-02
CN1757413A (zh) 2006-04-12
KR20010072564A (ko) 2001-07-31
HUP0101689A2 (hu) 2001-08-28
WO1999051258A1 (en) 1999-10-14
AU743824B2 (en) 2002-02-07
CN1303301A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
JP4148537B2 (ja) Ｃｄ４０ｃｒレセプター及びそれに対するリガンド
RU2263512C2 (ru) Средства, подавляющие отторжение трансплантата
JP2001502325A (ja) 免疫調整の方法および組成物
US20030026803A1 (en) Compositions for inhibiting macrophage activity
HUE031037T2 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
CN101072578A (zh) 用共刺激分子的联合癌症免疫疗法
US5942229A (en) Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent
KR20040036684A (ko) 치료용 결합 분자
US6472510B1 (en) CD40 receptor ligands
JP2840131B2 (ja) 液性免疫の持続性抑制方法
AU743824B2 (en) Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
ES2301164T3 (es) Slam, antigeno coestimulador de la superficie de celulas t.
US20020058037A1 (en) Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease
HK1067887A (en) Antibodies that bind the cd40cr receptor
JP2004261182A (ja) 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU7371801A (en) Methods of prolonged suppression of humoral immunity
MXPA97003956A (en) Purified genes that codify antigens of surface of mammali cells, proteins and antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060302

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081127